The success of B-cell-targeted therapies and compelling data from preclinical models of systemic lupus erythematosus (SLE) (2) have supported the use of CAR-T cell therapy in the disease, and clinical trials have demonstrated that CD19 CAR-T cell therapy rapidly induced and sustained remission in refractory SLE without the adverse events typically associated with CAR-T therapy (3). The gene discussed is CD19; the disease is systemic lupus erythematosus.